Drug intelligence / Profile preview

EV-D68 mAb

Development stage: Preclinical
Lead developer: Vanderbilt University Medical Center
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Intranasal, Intraperitoneal, Inhalation, Genetic

Overview

EV-D68 mAb is a monoclonal antibody being developed by IDBiologics for the treatment and prevention of respiratory illnesses caused by Enterovirus D68 (EV-D68). EV-D68 is a viral pathogen that can cause severe respiratory distress and has been associated with acute flaccid myelitis (AFM), a serious neurological condition. The antibody is designed to neutralize the virus, thereby reducing viral load and preventing the progression of the disease. It is currently part of IDBiologics' Global Public Health pipeline.

Other names: Enterovirus D68 monoclonal antibodyEV-D68 monoclonal antibodyEV-D-68 monoclonal antibodyEV-D 68 monoclonal antibody

Targets

Enterovirus D68 capsid VP1/VP3 epitopes

Beyond the preview

Go deeper on EV-D68 mAb.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EV-D68 mAb.

Explore the full profile